These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37995757)

  • 21. How Does Platelet-Rich Plasma Injection in Ovaries of Poor Responders Affect the Retrieved Oocytes, and Anti Mullerian Hormone: A Clinical Trial.
    Shahrokh Tehraninejad E; Razavi MO; Tarafdari Menshadi A; Shariat M; Shahsavari S; Haghollahi F; Azimi Nekoo E
    J Family Reprod Health; 2023 Sep; 17(3):165-173. PubMed ID: 38716292
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined Use of Autologous Bone Marrow-derived Stem Cells and Platelet-rich Plasma for Ovarian Rejuvenation in Poor Responders.
    Tandulwadkar S; Karthick MS
    J Hum Reprod Sci; 2020; 13(3):184-190. PubMed ID: 33311903
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A report on three live births in women with poor ovarian response following intra-ovarian injection of platelet-rich plasma (PRP).
    Farimani M; Heshmati S; Poorolajal J; Bahmanzadeh M
    Mol Biol Rep; 2019 Apr; 46(2):1611-1616. PubMed ID: 30725347
    [TBL] [Abstract][Full Text] [Related]  

  • 24. One Side Ovarian Rejuvenation: A Quasi-Experimental Study of the Effect of the Autologous Platelet Rich Plasma in Poor Ovarian Responders in IVF.
    Keikha F; Shahsavari S; Salari Y; Roozbeh N; Haghollahi F; Tarazjani MD; Razavi M; Shariat M; Bagheri M
    Ethiop J Health Sci; 2022 Nov; 32(6):1133-1140. PubMed ID: 36475267
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intraovarian platelet-rich plasma injection in poor responders.
    Devenutto LM; Valzacchi GR; Ercolano M; Etchegoyen O
    JBRA Assist Reprod; 2024 Aug; 28(3):450-456. PubMed ID: 38838163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cumulative delivery rate per aspiration IVF/ICSI cycle in POSEIDON patients: a real-world evidence study of 9073 patients.
    Esteves SC; Yarali H; Vuong LN; Carvalho JF; Özbek İY; Polat M; Le HL; Pham TD; Ho TM; Humaidan P; Alviggi C
    Hum Reprod; 2021 Jul; 36(8):2157-2169. PubMed ID: 34179973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. AMH has no role in predicting oocyte quality in women with advanced age undergoing IVF/ICSI cycles.
    Dai X; Wang Y; Yang H; Gao T; Yu C; Cao F; Xia X; Wu J; Zhou X; Chen L
    Sci Rep; 2020 Nov; 10(1):19750. PubMed ID: 33184364
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ovarian reserve and PGD treatment outcome in women with myotonic dystrophy.
    Srebnik N; Margalioth EJ; Rabinowitz R; Varshaver I; Altarescu G; Renbaum P; Levi-Lahad E; Weintraub A; Eldar-Geva T
    Reprod Biomed Online; 2014 Jul; 29(1):94-101. PubMed ID: 24813161
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intraovarian Platelet-rich Plasma Administration Induced Spontaneous Ovulation in an Anovulatory Woman With PCOS.
    Merhi Z; Mouanness M; Wang R; Seckin S
    JCEM Case Rep; 2023 Mar; 1(2):luad038. PubMed ID: 37908477
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ovarian Rejuvenation Through Platelet-Rich Autologous Plasma (PRP)-a Chance to Have a Baby Without Donor Eggs, Improving the Life Quality of Women Suffering from Early Menopause Without Synthetic Hormonal Treatment.
    Petryk N; Petryk M
    Reprod Sci; 2020 Nov; 27(11):1975-1982. PubMed ID: 32700285
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response-a randomized, controlled trial.
    Magnusson Å; Nilsson L; Oleröd G; Thurin-Kjellberg A; Bergh C
    Hum Reprod; 2017 Apr; 32(4):811-819. PubMed ID: 28175316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An update on platelet-rich plasma (PRP) therapy in endometrium and ovary related infertilities: clinical and molecular aspects.
    Hajipour H; Farzadi L; Latifi Z; Keyhanvar N; Navali N; Fattahi A; Nouri M; Dittrich R
    Syst Biol Reprod Med; 2021 Jun; 67(3):177-188. PubMed ID: 33632047
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Random anti-Müllerian hormone predicts ovarian response in women with high baseline follicle-stimulating hormone levels : anti-Müllerian hormone in poor responders in assisted reproductive treatment.
    Celik H; Bıldırcın D; Güven D; Cetinkaya MB; Alper T; Batuoğlu AS
    J Assist Reprod Genet; 2012 Aug; 29(8):797-802. PubMed ID: 22573035
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Maternal serum concentration of anti-Müllerian hormone is a better predictor than basal follicle stimulating hormone of successful blastocysts development during IVF treatment.
    Sadruddin S; Barnett B; Ku L; Havemann D; Mucowski S; Herrington R; Burggren W
    PLoS One; 2020; 15(10):e0239779. PubMed ID: 33044971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intraovarian platelet-rich plasma administration could improve blastocyst euploidy rates in women undergoing in vitro fertilization.
    Merhi Z; Seckin S; Mouanness M
    Clin Exp Reprod Med; 2022 Sep; 49(3):210-214. PubMed ID: 36097737
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Matrix-free 3D culture supports human follicular development from the unilaminar to the antral stage in vitro yielding morphologically normal metaphase II oocytes.
    Xu F; Lawson MS; Bean Y; Ting AY; Pejovic T; De Geest K; Moffitt M; Mitalipov SM; Xu J
    Hum Reprod; 2021 Apr; 36(5):1326-1338. PubMed ID: 33681988
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhancement of Ovarian Reserve and Oocyte Quality After Platelet-Rich Plasma Instillation in a Woman With Diminished Anti-Müllerian Hormone.
    Shrivastava J; More A; Shrivastava V; Choudhary N; Shrivastava D
    Cureus; 2024 Feb; 16(2):e53474. PubMed ID: 38440028
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does the anti-Müllerian hormone truly reflect ovarian response in women with endometrioma?
    Inal ZO; Engin Ustun Y; Yilmaz N; Aktulay A; Bardakci Y; Gulerman C
    J Obstet Gynaecol; 2019 May; 39(4):516-521. PubMed ID: 30744464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antral follicle count and anti-Müllerian hormone to classify low-prognosis women under the POSEIDON criteria: a classification agreement study of over 9000 patients.
    Esteves SC; Yarali H; Vuong LN; Carvalho JF; Özbek İY; Polat M; Le HL; Pham TD; Ho TM
    Hum Reprod; 2021 May; 36(6):1530-1541. PubMed ID: 33822057
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oocyte matched follicular fluid anti-Müllerian hormone is an excellent predictor of live birth after fresh single embryo transfer.
    Ciepiela P; Dulęba AJ; Kario A; Chełstowski K; Branecka-Woźniak D; Kurzawa R
    Hum Reprod; 2019 Nov; 34(11):2244-2253. PubMed ID: 31725884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.